Water Street Healthcare Partners sells off assets in the past three weeks. The strategic investor with special focus on the health care industry, Water Street Healthcare Partners, announced the recent sale of its outsourced pharmaceutical services firm AAIPharma Services Corp.
Medical
Edmond de Rothschild closes BioDiscovery 4 Fund
Edmond de Rothschild raises EUR192 million or USD250 million for its BioDiscovery 4 fund. The Edmond de Rothschild Investment Partners have announced the closure of its BioDiscovery 4 Venture capital fund for European life science companies.
Hookipa raises EUR20 million in Series B funding round
Hookipa Biotech AG, whose Vaxwave Technology, would help in the furtherance of infectious disease control and cancer management.
The Abraaj Group exits from Opalia Pharmaceuticals
The Abraaj Group sells its shares in Opalia Pharmaceuticals to Recordati. The Abraaj Group of Dubai recently announced it full exit from Opalia Pharma of Tunisia.
NovaQuest closes third fund at USD459 million
Novaquest Capital Management lands USD459 million for its Fund III. NovaQuest Capital Management had announced the closure of NovaQuest Pharma Opportunities Fund III LP.
Latest News
The approval for a bridge loan was given to McKesson to facilitate its acquisition of Celesio AG. The largest pharmaceutical distributor in the United States, McKesson Corp, had recently obtained a USD5.
ICU Medical Inc sought to sell itself but recent negotiations had broken down with one prospect, GTCR LLC.
The therapeutic protein molecule Anticalin would be the subject of the an agreement between Zydus and Pieris.
Albion Ventures, the largest venture capitalist in the UK completed the investment in Cisiv Ltd. Albion Ventures recently completed the acquisition of Cisiv Ltd.
immatics raises EUR34 million in its latest Series D round financing. Clinical stage biopharmaceutical firm immatics biotechnologies GmbH had developed advanced a multi-peptide vaccine program providing active medication against cancer.
Because of price caps and channel disruptions, the Indian drug market still is continuing its negative growth pattern.
Because of the failure to maintain good manufacturing standards, the UK regulatory authorities have withdrawn Wockhardt's certification of good standing.
The price of USD315 million is what KIK Customs paid for Chemtura Corp's consumer product business.
In its second largest acquisition in the past six months, KKR had acquired 30% of India's Gland Pharma for USD150 million.
